RVMD News and Press, Revolution Medicines Inc. From 11/07/22

Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RAS MULTI inhibitor) and RMC-6291 (KRAS G12C inhibitor) Completed successful equity financing to support advancement of pipeline Webcast t...

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, Nove...

KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to enter clinic, following closely behind company’s R...

Revolution Medicines ( NASDAQ: RVMD ) announces that Jack Anders, who previously served as the company’s senior VP, finance and principal financial and accounting officer, has been promoted to CFO, and Jeff Cislini, formerly VP, deputy general counsel, has been pr...

Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology ...

Revolution Medicines, Inc. (RVMD) Q2 2022 Earnings Conference Call August 09, 2022, 04:30 PM ET Company Participants David Arrington - SVP of IR and Corporate Affairs Mark Goldsmith - Chairman and CEO Jack Anders - SVP, Finance and Principal Accounting Officer ...

The following slide deck was published by Revolution Medicines, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Revolution Medicines, Inc. 2022 Q2 - Results - Earnings Call Presentation

Revolution Medicines press release ( NASDAQ: RVMD ): Q2 GAAP EPS of -$0.82 beats by $0.04 . Revenue of $9.11M (+4.7% Y/Y) beats by $2.09M . For further details see: Revolution Medicines GAAP EPS of -$0.82 beats by $0.04, revenue of $9.11M beats by $2.09M ...

First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers Appointment of industry experts in commercial oncology and financial str...

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, Au...